Vaderis Therapeutics

RougeTx

This biotechnology company develops small-molecule therapies that restore vascular stability to treat patients with hereditary haemorrhagic telangiectasia and other bleeding disorders.

Velorum Therapeutics

This company develops heme-sequestering biologic drugs for patients with lung cancer, rare genetic porphyrias and heme-induced tissue injuries.

Diagonal Therapeutics

This biotechnology company develops agonist antibody treatments for patients with rare genetic diseases like hereditary haemorrhagic telangiectasia and pulmonary arterial hypertension.

VASCULAR THERAPIES

This biotechnology company develops biodegradable collagen implants delivering sirolimus to improve vascular access outcomes for patients with kidney and vascular disease.

VascVersa Ltd

This company develops vascular cell therapies to regenerate blood vessels for patients with ischaemic diseases, chronic wounds, and retinal vascular conditions.

ProteoValent Therapeutics

This company develops targeted protein degrader therapies for cancer and haematology patients.

Actithera Group

This company develops radioligand therapies to treat cancer patients by delivering radiation directly to solid tumours while sparing healthy tissue.

Aptadir Therapeutics

The company develops RNA inhibitor-based therapeutics that reactivate silenced genes to treat patients with intractable cancers and rare genetic conditions.